SAN FRANCISCO – Less than 1 month of dual antiplatelet therapy (DAPT) followed by ticagrelor monotherapy post-percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation for acute coronary syndrome (ACS) met both the noninferiority and superiority thresholds in comparison with standard 12-month DAPT with ticagrelor and aspirin, primarily due to significant decreases in rates of major bleeding, a new study shows.